Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/31/2024 | $18.00 | Buy | H.C. Wainwright |
| 7/11/2024 | $11.00 | Overweight | Cantor Fitzgerald |
| 2/25/2022 | $24.00 → $12.00 | Buy → Hold | Jefferies |
WASHINGTON, Aug. 21, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that it has asked Martin Makary, the Commissioner of the U.S. Food and Drug Administration (FDA) to review the decision made by Jacqueline Corrigan-Curay, the departing director of the FDA's Center for Drug Evaluation and Research (CDER), days before her retirement that upholds an Office of Generic Drugs decision to approve two generic versions of Hetlioz®. In 2023, Vanda filed citizen petitions challenging the FDA's approval of two generic versions of Vanda's drug Hetlio
WASHINGTON, Aug. 18, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that it secured a landmark victory over the U.S. Food and Drug Administration (FDA) in its longstanding dispute with the agency regarding the approvability of HETLIOZ® (tasimelteon) to treat jet lag disorder (Vanda Pharmaceuticals Inc. v. FDA, case no. 24-1049). Vanda submitted its supplemental New Drug Application (sNDA) in October 2018 to market HETLIOZ® to treat jet lag disorder. After the FDA substantially delayed resolving Vanda's request for a hearing with respect t
Fanapt® Q2 2025 net product sales increased by 27% to $29.3 million compared to Q2 2024Bysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia accepted for filing; PDUFA target action date of February 21, 2026Tradipitant NDA for motion sickness accepted for filing; PDUFA target action date of December 30, 2025Imsidolimab BLA in generalized pustular psoriasis expected to be submitted in 2025WASHINGTON, July 31, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2025.
10-Q - Vanda Pharmaceuticals Inc. (0001347178) (Filer)
8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)
SCHEDULE 13G - Vanda Pharmaceuticals Inc. (0001347178) (Subject)
Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling
Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling
Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy
H.C. Wainwright initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $18.00
Cantor Fitzgerald initiated coverage of Vanda Pharma with a rating of Overweight and set a new price target of $11.00
Jefferies downgraded Vanda Pharmaceuticals from Buy to Hold and set a new price target of $12.00 from $24.00 previously
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
Fanapt® Q2 2025 net product sales increased by 27% to $29.3 million compared to Q2 2024Bysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia accepted for filing; PDUFA target action date of February 21, 2026Tradipitant NDA for motion sickness accepted for filing; PDUFA target action date of December 30, 2025Imsidolimab BLA in generalized pustular psoriasis expected to be submitted in 2025WASHINGTON, July 31, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2025.
Conference Call and Webcast to Follow WASHINGTON, July 23, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the second quarter 2025 on Thursday, July 31, 2025, before the market opens. Vanda will host a conference call at 8:00 AM ET on Thursday, July 31, 2025, during which management will discuss the second quarter 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 9430387. The conf
Fanapt® Q1 2025 total prescriptions (TRx) increased 14% compared to Q1 2024Fanapt® Q1 2025 new to brand prescriptions (NBRx) increased nearly threefold compared to Q1 2024Bysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia accepted for filing; PDUFA target action date of February 21, 2026Tradipitant NDA for motion sickness accepted for filing; PDUFA target action date of December 30, 2025Imsidolimab BLA in generalized pustular psoriasis expected to be submitted in 2025WASHINGTON, May 7, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced financial and operational results for the first quarter ended March 31, 2025. "Vanda has entered a new g
WASHINGTON, March 17, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the appointment of Tage Honoré, Ph.D., D.Sc. to its Board of Directors effective March 15, 2023. Following Dr. Honoré's appointment, Vanda's Board of Directors is now comprised of six directors, five of whom are independent. "Tage is a highly accomplished industry leader and respected scientist with deep experience across a diverse range of therapeutic areas," said Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board. "We are confident that his scientific expertise and executive experience will be invaluable, and look forward to working with him as we contin
SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)
SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)
SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)